Stay updated on PD-1 and NK Immunotherapy Combo in Solid Tumors Clinical Trial
Sign up to get notified when there's something new on the PD-1 and NK Immunotherapy Combo in Solid Tumors Clinical Trial page.

Latest updates to the PD-1 and NK Immunotherapy Combo in Solid Tumors Clinical Trial page
- Check5 days agoNo Change Detected
- Check13 days agoNo Change Detected
- Check20 days agoChange DetectedRevision: v3.4.2 was added and the funding/operating status notice (v3.4.1) was removed, with no changes to study data; to avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.5%

- Check27 days agoChange DetectedNotice added about a lapse in government funding and the NIH Clinical Center's operating status, with guidance to check cc.nih.gov and opm.gov. Revision history updated from v3.4.0 to v3.4.1.SummaryDifference0.5%

- Check34 days agoChange DetectedAdds a glossary display, introduces a 'Last Update Submitted that Met QC Criteria' label, adjusts capitalization for No FEAR Act Data, and updates the revision tag to v3.4.0. These are UI/metadata tweaks and do not affect core study contents or functionality. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.3%

- Check48 days agoChange DetectedThe only change is the revision label updated from v3.3.3 to v3.3.4; no substantive edits to the Study Details page. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.1%

- Check70 days agoChange DetectedAdded a Locations section showing Guangdong as a study site and updated the footer to Revision: v3.3.3; the prior Guangdong Locations and HHS Vulnerability Disclosure were removed.SummaryDifference0.3%

- Check99 days agoChange DetectedPublications section updated to clarify that entries are automatically filled from PubMed and may not be about the study, and the revision tag was updated to v3.3.2; the deletion note reiterates PubMed as the source with revision tag v3.2.0.SummaryDifference0.1%

Stay in the know with updates to PD-1 and NK Immunotherapy Combo in Solid Tumors Clinical Trial
Enter your email address, and we'll notify you when there's something new on the PD-1 and NK Immunotherapy Combo in Solid Tumors Clinical Trial page.